Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation: The PANTHEON International Project
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation : The PANTHEON International Project. / Poletti, Enrico; De Backer, Ole; Scotti, Andrea; Costa, Giuliano; Bruno, Francesco; Fiorina, Claudia; Buzzatti, Nicola; Latini, Alessia; Rudolph, Tanja K.; van den Dorpel, Mark M.P.; Brinkmann, Christina; Patel, Kush P.; Panoulas, Vasileios; Schofer, Joachim; Giordano, Arturo; Barbanti, Marco; Regazzoli, Damiano; Taramasso, Maurizio; Saia, Francesco; Baumbach, Andreas; Maisano, Francesco; Van Mieghem, Nicolas M.; Søndergaard, Lars; Latib, Azeem; Amat Santos, Ignacio J.; Bedogni, Francesco; Testa, Luca.
I: J A C C: Cardiovascular Interventions, Bind 16, Nr. 16, 2023, s. 1974-1985.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation
T2 - The PANTHEON International Project
AU - Poletti, Enrico
AU - De Backer, Ole
AU - Scotti, Andrea
AU - Costa, Giuliano
AU - Bruno, Francesco
AU - Fiorina, Claudia
AU - Buzzatti, Nicola
AU - Latini, Alessia
AU - Rudolph, Tanja K.
AU - van den Dorpel, Mark M.P.
AU - Brinkmann, Christina
AU - Patel, Kush P.
AU - Panoulas, Vasileios
AU - Schofer, Joachim
AU - Giordano, Arturo
AU - Barbanti, Marco
AU - Regazzoli, Damiano
AU - Taramasso, Maurizio
AU - Saia, Francesco
AU - Baumbach, Andreas
AU - Maisano, Francesco
AU - Van Mieghem, Nicolas M.
AU - Søndergaard, Lars
AU - Latib, Azeem
AU - Amat Santos, Ignacio J.
AU - Bedogni, Francesco
AU - Testa, Luca
N1 - Publisher Copyright: © 2023 American College of Cardiology Foundation
PY - 2023
Y1 - 2023
N2 - Background: Transcatheter aortic valve replacement (TAVR) in patients with pure severe native aortic valve regurgitation (NAVR) has been associated with suboptimal results. The available evidence concerns mostly outdated transcatheter heart valves (THVs). Objectives: The aim of this study was to investigate the performance of new-generation THVs in patients treated for pure severe NAVR. Methods: The PANTHEON (Performance of Currently Available Transcatheter Aortic Valve Platforms in Inoperable Patients With Pure Aortic Regurgitation of a Native Valve) study retrospectively included patients who underwent TAVR with currently available devices (both self-expanding [SE] and balloon expandable [BE]) for severe NAVR. Technical and device success rates as well as a composite of all-cause mortality and heart failure rehospitalization at 1 year were evaluated. The rate and clinical consequences of acute transcatheter valve embolization or migration (TVEM) were also considered. Results: A total of 201 patients were included. Overall technical and device success rates were 83.6% and 76.1%, respectively, and did not differ between SE and BE devices. These figures were due mostly to TVEM occurrence (14.6% vs 16.1%; P = 0.47) and residual moderate or greater aortic regurgitation (9.2% vs 10.1%; P = 0.87). Patients who experienced TVEM compared with those without TVEM had a significantly higher incidence of the composite endpoint at 1 year (25.7% vs 15.8%; P = 0.05). Conclusions: Despite improved THV platforms and techniques, TAVR for pure severe NAVR remains a challenging procedure, with significant risk for TVEM. SE and BE platforms demonstrated comparable performance in this setting. (Performance of Currently Available Transcatheter Aortic Valve Platforms in Inoperable Patients With Pure Aortic Regurgitation of a Native Valve [PANTHEON]; NCT05319171)
AB - Background: Transcatheter aortic valve replacement (TAVR) in patients with pure severe native aortic valve regurgitation (NAVR) has been associated with suboptimal results. The available evidence concerns mostly outdated transcatheter heart valves (THVs). Objectives: The aim of this study was to investigate the performance of new-generation THVs in patients treated for pure severe NAVR. Methods: The PANTHEON (Performance of Currently Available Transcatheter Aortic Valve Platforms in Inoperable Patients With Pure Aortic Regurgitation of a Native Valve) study retrospectively included patients who underwent TAVR with currently available devices (both self-expanding [SE] and balloon expandable [BE]) for severe NAVR. Technical and device success rates as well as a composite of all-cause mortality and heart failure rehospitalization at 1 year were evaluated. The rate and clinical consequences of acute transcatheter valve embolization or migration (TVEM) were also considered. Results: A total of 201 patients were included. Overall technical and device success rates were 83.6% and 76.1%, respectively, and did not differ between SE and BE devices. These figures were due mostly to TVEM occurrence (14.6% vs 16.1%; P = 0.47) and residual moderate or greater aortic regurgitation (9.2% vs 10.1%; P = 0.87). Patients who experienced TVEM compared with those without TVEM had a significantly higher incidence of the composite endpoint at 1 year (25.7% vs 15.8%; P = 0.05). Conclusions: Despite improved THV platforms and techniques, TAVR for pure severe NAVR remains a challenging procedure, with significant risk for TVEM. SE and BE platforms demonstrated comparable performance in this setting. (Performance of Currently Available Transcatheter Aortic Valve Platforms in Inoperable Patients With Pure Aortic Regurgitation of a Native Valve [PANTHEON]; NCT05319171)
KW - pure native aortic regurgitation
KW - transcatheter aortic valve replacement
KW - transcatheter valve embolization
U2 - 10.1016/j.jcin.2023.07.026
DO - 10.1016/j.jcin.2023.07.026
M3 - Journal article
C2 - 37648345
AN - SCOPUS:85168365044
VL - 16
SP - 1974
EP - 1985
JO - J A C C: Cardiovascular Interventions
JF - J A C C: Cardiovascular Interventions
SN - 1936-8798
IS - 16
ER -
ID: 397166428